A Phase 2, Open-label, Multicenter Study to Explore the Efficacy and Safety of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis

Trial Profile

A Phase 2, Open-label, Multicenter Study to Explore the Efficacy and Safety of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Mongersen (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 06 Sep 2017 This trial was completed in Bulgarian (on-2017-08-08), according to European Clinical Trials Database.
    • 31 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 27 Jul 2017 According to a celgene corporation media release, data from this trial is expected in second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top